Lv3
310 积分 2023-10-13 加入
P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBD
9个月前
已完结
Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors
10个月前
已完结
An update on factor XI structure and function
10个月前
已完结
Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
11个月前
已关闭
Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
11个月前
已关闭
Concizumab: First Approval
11个月前
已完结
Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study
11个月前
已完结
Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study
11个月前
已关闭
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
11个月前
已完结
MG1113, Anti-TFPI Antibody, Efficiently Recovers Coagulation Efficacy through Blocking the Kunitz 2 Domain of Human TFPI
1年前
已完结
皖公网安备34019202002308
